Healthcare >> CEO Interviews >> September 13, 2002

Wayne Yetter – Synavant Inc (snvt)

WAYNE YETTER is Chairman and Chief Executive Officer of SYNAVANT Inc., which was created in September 2000 as a spinoff from IMS HEALTH. SYNAVANT is a strategic solutions and services partner to the pharmaceutical and healthcare industries. Mr. Yetter joined IMS HEALTH as Chief Operating Officer in October 1999, responsible for growing global operations. Prior to joining IMS HEALTH, he served as President and Chief Executive Officer of Novartis Pharmaceuticals Corporation, the US division of Novartis AG. In this position, he successfully completed the merger of the Ciba-Geigy and Sandoz US pharmaceutical businesses. From 1991 to 1997, Mr. Yetter oversaw the development and growth of Astra Merck Inc., the industry's renowned greenfield opportunity to build a brand new pharmaceutical company. Within five years the company had 1,500 employees and generated revenues of $2 billion. Under his leadership, first as President and General Manager, then President and Chief Executive Officer, Prilosec' became the world's leading pharmaceutical product. In 1977, Mr. Yetter joined Merck & Co., serving in a variety of product management and marketing positions, including Vice President, Marketing Operations and Vice President, Far East/Pacific. From 1970 to 1977, he held sales and product management positions with the Pfizer Laboratories Division of Pfizer, Inc. Mr. Yetter earned a BA degree in Biology from Wilkes University in Wilkes- Barre, Pennsylvania, and an MBA degree from Bryant College in Smithfield, Rhode Island. He also served as a First Lieutenant with the Fourth Infantry Division in Vietnam. Mr. Yetter served on the Board of Directors of the Pharmaceutical Research and Manufacturers Association, the HealthCare Institute of New Jersey and the National Pharmaceutical Council. He is a member of the Board of Directors of Noven Pharmaceuticals, Inc., Transkaryotic Therapies, Inc., and the SEI Center for Advanced Studies in Management at the Wharton School, and is a member of the Board of Trustees of Wilkes University. Profile
TWST: Could you tell us a bit about what has gone on at SYNAVANT over

the past year or so that investors should be focusing on?

Mr. Yetter: The past year has been a very exciting one for